Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT05923008

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2023-11-29

182

Participants Needed

1

Research Sites

154 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI130. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI130, plan to enroll 20\~182 subjects,and a phase 2 to explore efficacy, safety and tolerability of IBI130 at RP2D in specified types of solid tumor.Approximately 150 evaluable subjects will be enrolled for phase 2.

CONDITIONS

Official Title

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand and provide written informed consent for all study procedures
  • Male or female aged 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Expected to live at least 12 weeks
  • Adequate bone marrow and organ function
Not Eligible

You will not qualify if you...

  • Currently enrolled in other interventional clinical trials except observational or follow-up phases
  • Received anti-tumor treatment within 4 weeks or 5 half-lives before starting study drug
  • Planning to receive other anti-tumor therapies during this study except palliative radiotherapy for symptom relief without affecting tumor assessment
  • Received live vaccines within 4 weeks before starting study drug or planning to receive live vaccines during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sunshine Coast University

Birtinya, Queensland, Australia, 4575

Actively Recruiting

Loading map...

Research Team

S

Serena Dong

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | DecenTrialz